| BACE1 | |
|---|---|
| Beta-Secretase 1 / Beta-Site APP Cleaving Enzyme 1 | |
| Protein Name | Beta-Secretase 1 |
| Gene | BACE1 |
| UniProt ID | Q15118 |
| PDB IDs | 1W0N, 2ZJD, 4N8H, 5W5C |
| Molecular Weight | ~70 kDa |
| Subcellular Localization | Endoplasmic reticulum, Golgi apparatus, endosomes |
| Protein Family | Aspartic protease, Peptidase A1 family |
Bace1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
BACE1 (Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1) is an aspartic protease that catalyzes the first and rate-limiting step in amyloid-beta (Aβ) production. It is a critical therapeutic target for Alzheimer's disease drug development.
BACE1 is a type I transmembrane protein with:
The protein folds into a typical aspartic protease structure with two lobes creating the active site cleft.
In the nervous system, BACE1 cleaves:
BACE1 is essential for:
BACE1 is central to the amyloidogenic pathway in Alzheimer's disease:
BACE1 inhibitors have been extensively investigated as AD therapeutics, but faced challenges:
Despite these challenges, BACE1 remains an important target, with next-generation inhibitors and alternative approaches being explored.
The study of Bace1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.